These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

566 related articles for article (PubMed ID: 22017035)

  • 1. A comparative evaluation of the protective efficacy of rMd5deltaMeq and CVI988/ Rispens against a vv+ strain of Marek's disease virus infection in a series of recombinant congenic strains of White Leghorn chickens.
    Chang S; Ding Z; Dunn JR; Lee LF; Heidari M; Song J; Ernst CW; Zhang H
    Avian Dis; 2011 Sep; 55(3):384-90. PubMed ID: 22017035
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative evaluation of vaccine efficacy of recombinant Marek's disease virus vaccine lacking Meq oncogene in commercial chickens.
    Lee LF; Kreager KS; Arango J; Paraguassu A; Beckman B; Zhang H; Fadly A; Lupiani B; Reddy SM
    Vaccine; 2010 Feb; 28(5):1294-9. PubMed ID: 19941987
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Host genetic resistance to Marek's disease sustains protective efficacy of herpesvirus of turkey in both experimental and commercial lines of chickens.
    Chang S; Xie Q; Dunn JR; Ernst CW; Song J; Zhang H
    Vaccine; 2014 Apr; 32(16):1820-7. PubMed ID: 24530405
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recombinant Marek's disease virus (MDV) lacking the Meq oncogene confers protection against challenge with a very virulent plus strain of MDV.
    Lee LF; Lupiani B; Silva RF; Kung HJ; Reddy SM
    Vaccine; 2008 Mar; 26(15):1887-92. PubMed ID: 18313812
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Properties of a meq-deleted rmd5 Marek's disease vaccine: protection against virulent MDV challenge and induction of lymphoid organ atrophy are simultaneously attenuated by serial passage in vitro.
    Lee LF; Kreager K; Heidari M; Zhang H; Lupiani B; Reddy SM; Fadly A
    Avian Dis; 2013 Jun; 57(2 Suppl):491-7. PubMed ID: 23901766
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cell culture attenuation eliminates rMd5ΔMeq-induced bursal and thymic atrophy and renders the mutant virus as an effective and safe vaccine against Marek's disease.
    Lee LF; Heidari M; Zhang H; Lupiani B; Reddy SM; Fadly A
    Vaccine; 2012 Jul; 30(34):5151-8. PubMed ID: 22687760
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Comparison of immunoprotection between vaccination with meq-deleted Marek's disease virus and vaccine strain CVI988/Rispens].
    Duan L; Su S; Wang Y; Li S; Sun P; Chen W; Cui Z
    Wei Sheng Wu Xue Bao; 2014 Nov; 54(11):1353-61. PubMed ID: 25752142
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of the Protection Efficacy of a Serotype 1 Marek's Disease Virus-Vectored Bivalent Vaccine Against Infectious Laryngotracheitis and Marek's Disease.
    Gimeno IM; Cortes AL; Faiz NM; Hernandez-Ortiz BA; Guy JS; Hunt HD; Silva RF
    Avian Dis; 2015 Jun; 59(2):255-62. PubMed ID: 26473676
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Detection and differentiation of CVI988 (Rispens vaccine) from other serotype 1 Marek's disease viruses.
    Gimeno IM; Dunn JR; Cortes AL; El-Gohary Ael-G; Silva RF
    Avian Dis; 2014 Jun; 58(2):232-43. PubMed ID: 25055627
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The efficacy of recombinant fowlpox vaccine protection against Marek's disease: its dependence on chicken line and B haplotype.
    Lee LF; Bacon LD; Yoshida S; Yanagida N; Zhang HM; Witter RL
    Avian Dis; 2004; 48(1):129-37. PubMed ID: 15077806
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of four very virulent Argentinian strains of Marek's disease virus and the influence of one of those isolates on synergism between Marek's disease vaccine viruses.
    Buscaglia C; Nervi P; Risso M
    Avian Pathol; 2004 Apr; 33(2):190-5. PubMed ID: 15276986
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serotype 1 viruses modified by backpassage or insertional mutagenesis: approaching the threshold of vaccine efficacy in Marek's disease.
    Witter RL; Kreager KS
    Avian Dis; 2004 Dec; 48(4):768-82. PubMed ID: 15666858
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Viral kinetics, shedding profile, and transmission of serotype 1 Marek's disease vaccine Rispens/CVI988 in maternal antibody-free chickens.
    Islam T; Renz KG; Walkden-Brown SW; Ralapanawe S
    Avian Dis; 2013 Jun; 57(2 Suppl):454-63. PubMed ID: 23901761
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protective efficacy of a recombinant bacterial artificial chromosome clone of a very virulent Marek's disease virus containing a reticuloendotheliosis virus long terminal repeat.
    Mays JK; Black-Pyrkosz A; Spatz S; Fadly AM; Dunn JR
    Avian Pathol; 2016 Dec; 45(6):657-666. PubMed ID: 27258614
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recombinant Gallid herpesvirus 2 with interrupted meq genes confers safe and efficacious protection against virulent field strains.
    Zhang Y; Liu C; Yan F; Liu A; Cheng Y; Li Z; Sun G; Lv H; Wang X
    Vaccine; 2017 Aug; 35(36):4695-4701. PubMed ID: 28754487
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A deletion in the glycoprotein L (gL) gene of U.S. Marek's disease virus (MDV) field strains is insufficient to confer increased pathogenicity to the bacterial artificial chromosome (BAC)-based strain, RB-1B.
    Shaikh SA; Katneni UK; Dong H; Gaddamanugu S; Tavlarides-Hontz P; Jarosinski KW; Osterrieder N; Parcells MS
    Avian Dis; 2013 Jun; 57(2 Suppl):509-18. PubMed ID: 23901769
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of diluting Marek's disease vaccines on the outcomes of Marek's disease virus infection when challenged with highly virulent Marek's disease viruses.
    Gimeno IM; Cortes AL; Montiel ER; Lemiere S; Pandiri AK
    Avian Dis; 2011 Jun; 55(2):263-72. PubMed ID: 21793444
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A recombinant field strain of Marek's disease (MD) virus with reticuloendotheliosis virus long terminal repeat insert lacking the meq gene as a vaccine against MD.
    Su S; Cui N; Zhou Y; Chen Z; Li Y; Ding J; Wang Y; Duan L; Cui Z
    Vaccine; 2015 Jan; 33(5):596-603. PubMed ID: 25562789
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro characterization of the Meq proteins of Marek's disease virus vaccine strain CVI988.
    Ajithdoss DK; Reddy SM; Suchodolski PF; Lee LF; Kung HJ; Lupiani B
    Virus Res; 2009 Jun; 142(1-2):57-67. PubMed ID: 19189855
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protection provided by Rispens CVI988 vaccine against Marek's disease virus isolates of different pathotypes and early prediction of vaccine take and MD outcome.
    Ralapanawe S; Walkden-Brown SW; Renz KG; Islam AF
    Avian Pathol; 2016; 45(1):26-37. PubMed ID: 26503904
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.